Insight Molecular Diagnostics (IMDX) Non-Current Deferred Tax Liability (2019 - 2023)

Insight Molecular Diagnostics has disclosed Non-Current Deferred Tax Liability across 3 years of filings, most recently posting $2.2 million for Q3 2023.

• Non-Current Deferred Tax Liability for Q3 2023 came in at $2.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $2.2 million (changed N/A YoY), and the FY2019 annual result was $3.8 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability came in at $2.2 million for Q3 2023 at Insight Molecular Diagnostics, roughly flat from $2.2 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.8 million in Q4 2019 to a low of $158000.0 in Q1 2020.
• The 3-year median for Non-Current Deferred Tax Liability is $2.2 million (2023), against an average of $1.6 million.